Vascularizing lymph node dissection for advanced gastric cancer: A single-institution experience

Table 1 Clinicopathological characteristics of patients

Group	VLND	NVLND	P value
No. of cases	152	163
Sex
Male	101	101	0.414
Female	51	62
Age (yr), mean ± SD	55.72 ± 11.73	56.97 ± 12.19	0.163
Tumor location
Upper stomach	38	46	0.679
Middle stomach	36	42
Lower stomach	75	70
Whole stomach	3	5
Tumor size (cm), mean ± SD	4.59 ± 2.84	4.38 ± 3.29	0.456
Bormann type
I or II	40	57	0.063
III or IV	112	106
Postoperative stay (d)	13.24	13.96	0.473
Blood transfusion			0.982
Absent	94	101
Present	58	62
Mean operation time	271.91 ± 65.58	272.52 ± 57.57	0.931
Gastrectomy			0.129
Total	58	76
Subtotal	94	87
Type of reconstruction
Roux-en-Y	58	76
Billroth I	7	9
Billroth II	87	78
Pathological classification and differentiation			0.466
Differentiated	53	47
Undifferentiated	99	115
Retrieved nodes, mean ± SD	29.94 ± 11.70	27.85 ± 12.05	0.307
Metastatic nodes, mean ± SD	4.41 ± 7.54	5.30 ± 7.33	0.717
pT stage			0.406
T1	25	22
T2	21	14
T3	70	84
T4	36	43
pN stage			0.546
N0	61	53
N1	57	66
N2	22	28
N3	12	16

VLND: Vascularizing lymph node dissection; NVLND: Non-vascularizing lymph node dissection.

Table 2 Postoperative complications after gastrectomy

Complication	VLND	NVLND	P value
Anastomotic leakage	1	1
Duodenal stump leak	1	2
Biliary fistula	2	0
Pancreatic fistula	1	0
Ileus	2	4
Lymphorrhea	2	0
Abdominal hemorrhage	3	1
Intra-abdominal infection	3	5
Pulmonary complications	3	4
Catheter-related infection	2	2
Total	20	19	0.686

VLND: Vascularizing lymph node dissection; NVLND: Non-vascularizing lymph node dissection.